FDA Accepts sBLA for Mosunetuzumab Plus Polatuzumab Vedotin in LBCL
Click to view quick news summary (Spoiler)
The FDA is reviewing a supplemental biologics license application for subcutaneous mosunetuzumab combined with polatuzumab vedotin. This fixed-duration, chemo-free, and outpatient-ready regimen demonstrated a 59% reduction in progression or death risks during the Phase 3 SUNMO study for relapsed/refractory large B-cell lymphoma.
FDA reviews chemo-free mosunetuzumab plus polatuzumab for relapsed/refractory LBCL, promising outpatient second-line care and longer PFS. The FDA has accepted a supplemental biologics application (sBLA) for subcutaneous mosunetuzumab-axgb (Lunsumio VELO) in combination with polatuzumab vedotin (Polivy) for adults with relapsed or refractory large B-cell lymphoma (LBCL) who have received at least 1 prior line of systemic therapy. The regulatory body is expected to make a decision by February 9, 2027, which, if approved, could offer a chemotherapy-free, outpatient-ready option in this setting.
The second-line setting is a narrow window in which delays related to referral, transplant-center coordination, or travel can affect outcomes for patients with relapsed or refractory disease. An outpatient-ready, fixed-duration option that does not require transplant eligibility could allow more patients to start effective second-line treatment closer to home, without the logistical lead time that more intensive regimens often require.
"When treating [LBCL], the second-line setting represents a critical window where we must act quickly with effective therapies," Tara M. Graff, DO, MS, director of clinical research at Mission Cancer and Blood, stated in a news release. "Current advanced therapies may present complex logistical and geographical barriers for many patients. Since most patients in the US are treated in the community setting, we need more chemotherapy-free, outpatient-ready treatments, like mosunetuzumab and polatuzumab vedotin."
Key Takeaways from the SUNMO Trial
- FDA review is underway for subcutaneous mosunetuzumab plus polatuzumab vedotin in R/R LBCL after ≥1 prior line, potentially enabling chemotherapy-free, outpatient delivery with fixed duration.
- Time-to-treatment barriers in second-line LBCL—referral delays, transplant-center logistics, and travel—may be mitigated by a non-transplant-dependent regimen suitable for community practice.
- SUNMO randomized 208 transplant-ineligible patients 2:1 versus R-GemOx; dual primary endpoints were PFS and ORR, with OS, DoR, CR rate, safety, and PROs secondary.
- At 23.2 months’ median follow-up, mosunetuzumab/polatuzumab reduced progression/death risk by 59% (HR 0.41) and extended median PFS to 11.5 vs 3.8 months.
- Safety aligned with established profiles; CRS occurred in ~25% with <5% grade 2–3, and longer follow-up continued to show sustained PFS benefit in second-line patients.
